Ron jankov biography

Ronald Jankov General Information.
Ronald Jankov biography.
Ronald Steven Jankov has an estimated net worth of $29.3 Million.

•

Abstract

Hyaluronan (HA), a large glycosaminoglycan found in the ECM, has major roles in lung and vascular biology and disease. However, its role in idiopathic pulmonary arterial hypertension (IPAH) is unknown. We hypothesized that HA metabolism is abnormal in IPAH. We measured the plasma levels of HA in IPAH and healthy individuals. We also evaluated HA synthesis and the expression of HA synthases and hyaluronidases in pulmonary artery smooth muscle cells (PASMCs) from explanted lungs. Plasma HA levels were markedly elevated in IPAH compared with controls [HA (ng/ml, mean ± SD): IPAH 325 ± 80, control 28 ± 9; P = 0.02]. In vitro, unstimulated IPAH PASMCs produced high levels of HA compared with control cells [HA in supernatant (μg/ml, mean ± SD): IPAH 12 ± 2, controls 6 ± 0.9; P = 0.04]. HA levels were also higher in IPAH PASMC lysates. The increased HA was biologically relevant as shown by tissue staining and increased HA-specific binding of mononuclear cells to IPAH compared with control PASMCs [number of bound cells × 10⁴ (mean ± SD): IPAH 9.5 ± 3, control 3.0 ± 1; P

•

$29.3 Million

Estimate Recalculated Nov 8, 2024 04:39PM EST

Who is Ronald Steven Jankov?

Ronald Steven Jankov has an estimated net worth of $29.3 Million. This is based on reported shares across multiple companies, which include XILINX INC, Knowles Corp, and NETLOGIC MICROSYSTEMS INC.

SEC CIK

Ronald Steven Jankov's CIK is 0001296432

Past Insider Trading and Trends

2007 was Ronald Steven Jankov's most active year for acquiring shares with 12 total transactions. Ronald Steven Jankov's most active month to acquire stocks was the month of January. 2012 was Ronald Steven Jankov's most active year for disposing of shares, totalling 30 transactions. Ronald Steven Jankov's most active month to dispose stocks was the month of January. 2011 saw Ronald Steven Jankov paying a total of $2,378,017.55 for 311,760 shares, this is the most they've acquired in one year. In 2011 Ronald Steven Jankov cashed out on 616,010 shares for a total of $16,781,746.80, their largest year based on trade value.

Attention insiders: Dive deeper into market movemen

•

LASIK

Corrective ophthalmological surgery

Not to be confused with Lasic or Lassik.

For the drug used for hypertension, see Lasix. For the Slovakian footballer, see Richard Lásik.

Medical intervention

LASIK or Lasik (; "laser-assisted in situkeratomileusis"), commonly referred to as laser eye surgery or laser vision correction, is a type of refractive surgery for the correction of myopia, hyperopia, and astigmatism.^[1] LASIK surgery is performed by an ophthalmologist who uses a femtosecond laser or a microkeratome to create a corneal flap to expose the corneal stroma and then an excimer laser to reshape the corneal stroma in order to improve visual acuity.^[2]^[3]

LASIK is very similar to another surgical corrective procedure, photorefractive keratectomy (PRK), and LASEK. All represent advances over radial keratotomy in the surgical treatment of refractive errors of vision. For people with moderate to high myopia or thin corneas which cannot be treated with LASIK or PRK, the phakic intraocular lens is an alternative.^[4]^[5&#